Evaluation of Mutations and Gene Expression in AML Patients.

BACKGROUND & OBJECTIVE: Acute myeloid leukemia (AML) is a hematopoietic malignancy caused by genetic abnormalities. Currently, molecular and genetic factors are routinely used as diagnostic and prognostic markers. FLT-3 is one of the most known diagnostic factors in AML. gene belongs to the ATP binding cassette family; it is known as one of the chemotherapy-resistant causes of AML. We aimed to study mutations and their association with gene expression in AML individuals.

METHODS

For investigation, 80 AML individuals and 20 healthy controls were selected. This study was done in the Cancer molecular Pathology Research Center of Mashhad University of Medical Sciences (MUMS), Iran during 2017-2019. mutation was assessed by polymerase chain reaction (PCR); Real-time quantitative PCR was performed to measure the amount of gene expression. Bone marrow and blood smears of patients were evaluated in terms of morphology. SPSS 16.0 was used for data analysis.

RESULTS

mutation and overexpression were found in 18.8% and 23.8% of AML patients, respectively. Statistical analysis did not show any relationship or association between these two markers. Cuplike morphology was observed in blast cells in 21.25% of AML cases, which was associated with the presence of mutation.

CONCLUSION

and function independently. Survival studies to determine the exact role of overexpression in drug resistance issues would be suggested.